) The Developmental Research Program of the SPORE in Ovarian Cancer is a vital mechanism for new scientific direction and career development. Through this mechanism, new technology, innovative but risky basic science ideas, and innovative """"""""translational"""""""" clinical applications of basic findings can be applied and tested. In addition, the Developmental Research Program provides opportunities for young investigators to compete at an institutional level """"""""only,"""""""" thus increasing the chances for funding of developmental ideas. This program can potentially be used as well in the recruitment package for young investigators identified through the Career Development Program who have innovative ideas suitable for funding at initiation of their employment. We have allocated $200,000 for this purpose and, as noted previously, have an additional $200,000 annually in institutional commitments to this Developmental Research Program. We intend to fund six to eight projects at the $50,000 or greater level per year. These awards are intended for one year; however, a review of progress and potential will occur at 10 months, with the possibility of additional funding for a second year to clearly successful projects that have real potential for further contribution to the SPORE if an additional year of funding is added. It is, of course, the intent of the program that the developmental projects lead rapidly to pursuit of RO1 (or equivalent) funding or that insolvable problems be recognized early to avoid wasting resources.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
3P50CA083591-04S1
Application #
6662780
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2002-09-30
Project End
2003-09-29
Budget Start
Budget End
Support Year
4
Fiscal Year
2002
Total Cost
Indirect Cost
Name
University of Alabama Birmingham
Department
Type
DUNS #
004514360
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Skates, Steven J; Greene, Mark H; Buys, Saundra S et al. (2017) Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening Trials. Clin Cancer Res 23:3628-3637
Ren, Yi A; Mullany, Lisa K; Liu, Zhilin et al. (2016) Mutant p53 Promotes Epithelial Ovarian Cancer by Regulating Tumor Differentiation, Metastasis, and Responsiveness to Steroid Hormones. Cancer Res 76:2206-18
Nelson, Carol A; Azure, Michael T; Adams, Christopher T et al. (2014) The somatostatin analog 188Re-P2045 inhibits the growth of AR42J pancreatic tumor xenografts. J Nucl Med 55:2020-5
Kim, Kenneth H; Dmitriev, Igor; O'Malley, Janis P et al. (2012) A phase I clinical trial of Ad5.SSTR/TK.RGD, a novel infectivity-enhanced bicistronic adenovirus, in patients with recurrent gynecologic cancer. Clin Cancer Res 18:3440-51
Kimball, Kristopher J; Preuss, Meredith A; Barnes, Mack N et al. (2010) A phase I study of a tropism-modified conditionally replicative adenovirus for recurrent malignant gynecologic diseases. Clin Cancer Res 16:5277-87
Borovjagin, Anton V; McNally, Lacey R; Wang, Minghui et al. (2010) Noninvasive monitoring of mRFP1- and mCherry-labeled oncolytic adenoviruses in an orthotopic breast cancer model by spectral imaging. Mol Imaging 9:59-75
Szafran, April Adams; Folks, Karri; Warram, Jason et al. (2009) Death receptor 5 agonist TRA8 in combination with the bisphosphonate zoledronic acid attenuated the growth of breast cancer metastasis. Cancer Biol Ther 8:1109-16
Matsumura, Noriomi; Huang, Zhiqing; Baba, Tsukasa et al. (2009) Yin yang 1 modulates taxane response in epithelial ovarian cancer. Mol Cancer Res 7:210-20
Bell, Walter C; Sexton, Katherine C; Grizzle, William E (2009) How to efficiently obtain human tissues to support specific biomedical research projects. Cancer Epidemiol Biomarkers Prev 18:1676-9
Meredith, Ruby F; Shen, Sui; Forero, Andres et al. (2008) A method to correct for radioactivity in large vessels that overlap the spine in imaging-based marrow dosimetry of lumbar vertebrae. J Nucl Med 49:279-84

Showing the most recent 10 out of 114 publications